导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.11% | 2971/4773 |
| 近一周 | -1.27% | 1926/5465 |
| 近一月 | -1.12% | 1041/5421 |
| 近一季 | 0.47% | 911/5231 |
| 近半年 | -0.12% | 1412/4920 |
| 近一年 | 1.42% | 2488/4394 |
| 近两年 | 36.47% | 2055/2954 |
| 近三年 | 23.90% | 1348/2253 |
| 成立以来 | 37.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.00% 3999/4961 |
6.72% 2800/5312 |
- - |
- - |
| 2025 | 16.31% 2467/4813 |
-0.15% 2086/3635 |
3.06% 1180/4076 |
10.59% 3271/4524 |
2.20% 1049/4813 |
| 2024 | 16.57% 793/3463 |
3.63% 533/2808 |
-0.52% 781/3014 |
16.40% 1468/3129 |
-2.86% 2193/3463 |
| 2023 | -7.26% 903/2656 |
1.15% 1631/2280 |
-4.01% 1013/2385 |
2.03% 259/2515 |
-6.39% 1748/2655 |
| 2022 | -16.32% 472/2207 |
-10.89% 448/1919 |
6.58% 659/2016 |
-12.67% 758/2113 |
0.90% 1434/2208 |
| 2021 | -2.67% 865/1822 |
-1.75% 537/1255 |
2.56% 996/1330 |
-5.55% 823/1466 |
2.27% 641/1822 |
| 2020 | 30.08% 526/1250 |
-10.91% 809/1028 |
11.98% 707/1067 |
15.87% 189/1164 |
12.53% 457/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 东财上证50ETF发起式联接A VS. 长安沪深300非周期A(740101) |